Drugs / MABEL CTLs
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02287311 | Feb 2015 → Jan 2024 overdue | Hodgkins lymphoma, T-cell and NK-cell neoplasm, nasopharyngeal carcinoma, non-Hodgkin lymphoma +1 | Baylor College of Medicine | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MABEL CTLs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02287311 ↗ |
| Action | Deplete | “trained to kill EBV infected cells” NCT02287311 ↗ |
| Modality | Cell therapy | “special immune system cells called LMP, BARF-1 and EBNA1- specific cytotoxic T lymphocytes (MABEL CTLs)” NCT02287311 ↗ |